BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew Sells 536 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) EVP Aby J. Mathew sold 536 shares of BioLife Solutions stock in a transaction dated Monday, July 7th. The shares were sold at an average price of $22.27, for a total value of $11,936.72. Following the completion of the sale, the executive vice president directly owned 352,582 shares in the company, valued at approximately $7,852,001.14. This represents a 0.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

BioLife Solutions Stock Performance

BioLife Solutions stock traded down $0.77 during midday trading on Friday, reaching $21.95. 266,696 shares of the company's stock were exchanged, compared to its average volume of 419,786. BioLife Solutions, Inc. has a 52 week low of $19.10 and a 52 week high of $29.55. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.74 and a current ratio of 4.73. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of -75.69 and a beta of 1.79. The stock's 50-day simple moving average is $22.31 and its 200 day simple moving average is $24.32.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.07. BioLife Solutions had a negative return on equity of 0.66% and a negative net margin of 11.81%. The business had revenue of $23.94 million during the quarter, compared to analysts' expectations of $22.22 million. On average, analysts expect that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BioLife Solutions

A number of hedge funds and other institutional investors have recently bought and sold shares of BLFS. Invesco Ltd. grew its position in shares of BioLife Solutions by 9.6% in the first quarter. Invesco Ltd. now owns 3,551,054 shares of the medical equipment provider's stock valued at $81,106,000 after purchasing an additional 311,585 shares during the last quarter. Fred Alger Management LLC grew its position in shares of BioLife Solutions by 1.0% in the fourth quarter. Fred Alger Management LLC now owns 1,594,221 shares of the medical equipment provider's stock valued at $41,386,000 after purchasing an additional 16,274 shares during the last quarter. T. Rowe Price Investment Management Inc. acquired a new position in shares of BioLife Solutions in the first quarter valued at approximately $30,789,000. Millennium Management LLC grew its position in shares of BioLife Solutions by 49.1% in the fourth quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider's stock valued at $29,733,000 after purchasing an additional 377,111 shares during the last quarter. Finally, Palisade Capital Management LP grew its position in shares of BioLife Solutions by 13.7% in the first quarter. Palisade Capital Management LP now owns 947,085 shares of the medical equipment provider's stock valued at $21,631,000 after purchasing an additional 113,937 shares during the last quarter. Institutional investors own 93.24% of the company's stock.

Wall Street Analysts Forecast Growth

BLFS has been the topic of a number of recent research reports. Wall Street Zen downgraded BioLife Solutions from a "hold" rating to a "sell" rating in a research report on Wednesday, May 21st. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 target price on shares of BioLife Solutions in a research report on Tuesday, May 13th. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $31.17.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.